HKSE · 9969.HK
InnoCare Pharma Limited
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
Loading market information…
HKSE · 2617.HK · HKD
Stock price
Quote as of Oct 30, 2026, 03:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$28.02-HK$0.20 (-0.71%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
HK$23.60-HK$1.36 (-5.45%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$1.58HK$0.00 (0.0%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
HK$3.29-HK$0.04 (-1.05%)
BioDlink International Company Limited’s quoted price sits in the lower half of its reported 52-week range, 43.95% below the high.
HK$5.67+HK$0.04 (+0.62%)
Laekna, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.71% below the high.
HK$2.87+HK$0.05 (+1.59%)
Antengene Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 54.3% below the high.
